PMID: 11604362Oct 18, 2001Paper

Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome

Bulletin du cancer
M Attal, J L Harousseau

Abstract

This article summarizes the different clinical results of the IFM trials: high dose therapy supported with autologous stem cells improves survival, melphalan 200 mg/m2 is the best preparative regimen, unpurged peripheral blood stem cells are the recommended source of stem-cells to support high dose therapy, tandem transplants significantly improve survival. However, despite these encouraging results, long term survival needs inovative strategies evaluated with the current IFM 99 protocol.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Baillière's Best Practice & Research. Clinical Haematology
M Attal, J L Harousseau
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
C A LinkerJ L Wolfe
Hematology/oncology Clinics of North America
M Attal, J L Harousseau
© 2021 Meta ULC. All rights reserved